The secondary outcomes are changes in glucose area under the curve (AUC) in an OGTT, changes in insulin secretion and insulin sensitivity, and incident cardiovascular disease (CVD) events (fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, death from cardiovascular causes or incident heart failure). This evidence concerns the gene INS and heart failure.